Autologous Stem Cell Transplantation for the Treatment of Neuroblastoma in Korea

Journal of Korean Medical Science

Volumn 18, Issue 2, 2003, Pages 242-247

  Ryu, Kyung Ha ^a   Ahn, Hyo Seop ^b,m   Koo, Hong Hoe ^c   Kook, Hoon ^d   Kim, Moon Kyu ^e   Kim, Hack Ki ^f   Ghim, Thad ^g   Moon, Hyung Nam ^g   Seo, Jong Jin ^g   Sung, Ki Woong ^c   Shin, Hee Young ^b   Yoo, Eun Sun ^a   Lyu, Chuhl Joo ^h   Lee, Young Ho ⁱ   Lee, Hahng ^j   Cho, Bin ^f   Cho, Hyun Sang ^k   Choi, Hyung Soo ^b   Hah, Jeong Ok ^l   Hwang, Tai Ju ^d  

^a Ewha Womans University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Ajou University School of Medicine   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Dong A University   (South Korea)

^j Hanyang University   (South Korea)

^k Hallym University   (South Korea)

^l Yeungnam University College of Medicine   (South Korea)

^m Seoul National University Children's Hospital   (South Korea)

more..

Author keywords

Korea; Neuroblastoma; Stem Cell Transplantation

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 2; ISOTRETINOIN; MELPHALAN; TENIPOSIDE; VINCRISTINE;

ADOLESCENT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; HUMAN; INFANT; KOREA; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; ONCOGENE C MYB; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 10744224594     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2003.18.2.242     Document Type: Review

References (20)

1. Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 1991; 38: 393-424.
2. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, Hasse GM, Stream DO, Seeger RC. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent children's cancer group results. Eur J Cancer 1995; 31A: 572-5.
3. Bowman LC, Hancock ML, Santana VM, Hayes FA, Kun L, Parham DM, Furman WL, Rao BN, Green AA. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St. Jude Children's Research Hospital Experience, 1962 to 1988. J Clin Oncol 1991; 9: 1599-608.
4. Matthay KK, Harris R, Reynolds CP. Improved event-free survival for autologous bone marrow transplantation versus chemotherapy in neuroblastoma: A phase III randomized Childrens Cancer Group Study. Proc Amer Soc Clin Oncol 1998; 17: 525a.
5. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Prichard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D. Multivariate analysis of risk factors in stage 4 neuroblastoma over the age of one year treated with mega-therapy and stem cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16: 953.
6. Castleberry RP. Biology and treatment of neuroblastoma. Pediatr Clin North Am 1997; 44: 919-37.
7. Ladenstein R, Phillip T, Gardner H. Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr 1997; 9: 55-69.
8. Moss TJ, Sanders DG, Lasky LC, Bosdtom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879-83.
9. Johnson FL, Goldman S. Role of autotransplantation in neuroblastoma. Hematol Oncol Clin North Am 1993; 7: 647-62.
10. Laver JJ, Klann R, Kletzel M. Comparison of the presence of tumor cells in purged marrow versus peripheral blood in stem cell grafts for neuroblastoma. Cancer Res 1998; 58: 2925-8.
11. Kuroda T, Saeki M, Nakano M, Mizutani S. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. J Pediatr Surg 1997; 32: 69-72.
12. + cell transplantation in children with neuroblastoma. Med Pediatr Oncol 2000; 35: 1-7.
13. + progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 1997; 6: 235-42.
14. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Children's Cancer Group Pilot Study. J Clin Oncol 1993; 11: 2226-33.
15. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-3.
16. Ross AA. Minimal residual disease in solid tumor malignancies: a review. J Hematother 1998; 7: 9-18.
17. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998; 91: 1706-15.
18. Vivancos P, Grañena A. Treatment with interleukin-2 (IL-2) and interferon after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Bone Marrow Transplant 1999; 23: 169-72.
19. Sondel PM, Hank JA. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Cancer J Sci Am 1997; 1: S121-7.
20. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphology differentiation of human neuroblastoma. Nature 1985; 313: 404-6.